Physicians also expect greater use of Johnson & Johnson’s Varipulse system over the next two years despite the company’s ...

Johnson & Johnson executives, on a Wednesday earnings call, did not provide a timeline for when U.S. Varipulse cases will ...

(Reuters) -Johnson & Johnson said on Wednesday it had temporarily paused the rollout of its Varipulse heart device in the United States, as the company investigates four reported stroke events. The ...

Opens in a new tab or window Just months after FDA approval, Johnson & Johnson paused the rollout of its Varipulse pulsed field ablation (PFA) platform in the U.S. due to safety reasons.

Shares in the NYSE-listed company dropped 2.8% at market open following the earnings, possibly a reflection of 2025 guidance.

All ablation cases set to use the Varipulse pulsed-field ablation (PFA) system have been temporarily halted in the United States after four neurovascular events were reported during an external ...

Johnson & Johnson’s JNJ MedTech unit has temporarily paused sales of Varipulse, its pulsed field ablation (PFA) therapy to treat atrial fibrillation (AFib) in the United States, as it ...

Johnson & Johnson (NYSE: JNJ) shares dipped slightly before hours today on fourth-quarter results that topped the consensus ...

Johnson & Johnson said Wednesday it paused all U.S. Varipulse cases while the company investigates the cause of four reported neurovascular events. J&J said the cases were part of an external ...

J&J said it temporarily paused the use of the heart device, Varipulse, while it probes the cause of four reported “neurovascular events” in patients. J&J said the pause doesn’t affect ...

Jan 8 (Reuters) - Johnson & Johnson (JNJ.N), opens new tab said on Wednesday it had temporarily paused the rollout of its Varipulse heart device in the United States, as the company investigates ...